[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628557":3},{"organization":4,"armGroups":7,"interventions":28,"overallOfficials":41,"centralContacts":45,"locations":51,"responsibleParty":198,"collaborators":40,"id":200,"slug":201,"hasResults":202,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":40,"eligibilityCriteria":206,"healthyVolunteers":202,"sex":207,"minAge":208,"maxAge":209,"enrollmentInfo":210,"targetDuration":40,"studyType":213,"phases":214,"briefSummary":216,"conditions":217,"keywords":40,"overallStatus":54,"whyStopped":40,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":229},{"fullName":5,"class":6},"Merck Sharp & Dohme LLC","INDUSTRY",[8,14,20,24],{"label":9,"type":10,"description":11,"interventionNames":12},"Period 1: MK-8690","EXPERIMENTAL","Participants will receive MK-8690 via subcutaneous injection for 12 weeks.",[13],"Drug: MK-8690",{"label":15,"type":16,"description":17,"interventionNames":18},"Period 1: Placebo","PLACEBO_COMPARATOR","Participants will receive placebo via subcutaneous injection for 12 weeks.",[19],"Other: Placebo",{"label":21,"type":10,"description":22,"interventionNames":23},"Period 2: MK-8690","Participants who do not respond to treatment in Period 1 (regardless of treatment assignment in Period 1) will receive MK-8690 via subcutaneous injection for 12 weeks.",[13],{"label":25,"type":10,"description":26,"interventionNames":27},"Period 3: MK-8690","Participants who respond to treatment in either Period 1 or Period 2 will receive additional MK-8690 via subcutaneous injection for up to approximately 42 weeks.",[13],[29,36],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"DRUG","MK-8690","Solution for subcutaneous injection",[9,21,25],[35],"PRA052",{"type":37,"name":38,"description":32,"armGroupLabels":39,"otherNames":40},"OTHER","Placebo",[15],null,[42],{"name":43,"affiliation":5,"role":44},"Medical Director","STUDY_DIRECTOR",[46],{"name":47,"role":48,"phone":49,"phoneExt":40,"email":50},"Toll Free Number","CONTACT","1-888-577-8839","Trialsites@msd.com",[52,70,83,95,108,120,133,146,159,172,186],{"facility":53,"status":54,"city":55,"state":56,"zip":57,"country":58,"countryCode":59,"cosmosGeoPoint":60,"geoPoint":65,"contacts":66},"Clinnova Research ( Site 1042)","RECRUITING","Anaheim","California","92805","United States","US",{"type":61,"coordinates":62},"Point",[63,64],-117.9145,33.83529,{"lat":64,"lon":63},[67],{"name":68,"role":48,"phone":69,"phoneExt":40,"email":40},"Study Coordinator","949-889-0249",{"facility":71,"status":54,"city":72,"state":73,"zip":74,"country":58,"countryCode":59,"cosmosGeoPoint":75,"geoPoint":79,"contacts":80},"Peak Gastroenterology Associates ( Site 1052)","Colorado Springs","Colorado","80907",{"type":61,"coordinates":76},[77,78],-104.82136,38.83388,{"lat":78,"lon":77},[81],{"name":68,"role":48,"phone":82,"phoneExt":40,"email":40},"719-636-1201",{"facility":84,"status":54,"city":85,"state":73,"zip":86,"country":58,"countryCode":59,"cosmosGeoPoint":87,"geoPoint":91,"contacts":92},"South Denver Gastroenterology, PC ( Site 1068)","Englewood","80113",{"type":61,"coordinates":88},[89,90],-104.98776,39.64777,{"lat":90,"lon":89},[93],{"name":68,"role":48,"phone":94,"phoneExt":40,"email":40},"303-406-4288",{"facility":96,"status":54,"city":97,"state":98,"zip":99,"country":58,"countryCode":59,"cosmosGeoPoint":100,"geoPoint":104,"contacts":105},"Nature Coast Clinical Research ( Site 1045)","Inverness","Florida","34452",{"type":61,"coordinates":101},[102,103],-82.33037,28.83582,{"lat":103,"lon":102},[106],{"name":68,"role":48,"phone":107,"phoneExt":40,"email":40},"352-341-2100",{"facility":109,"status":54,"city":110,"state":98,"zip":111,"country":58,"countryCode":59,"cosmosGeoPoint":112,"geoPoint":116,"contacts":117},"Research Associates of South Florida - Miami - Southwest 8th Street ( Site 1072)","Miami","33134",{"type":61,"coordinates":113},[114,115],-80.19366,25.77427,{"lat":115,"lon":114},[118],{"name":68,"role":48,"phone":119,"phoneExt":40,"email":40},"786-476-8790",{"facility":121,"status":54,"city":122,"state":123,"zip":124,"country":58,"countryCode":59,"cosmosGeoPoint":125,"geoPoint":129,"contacts":130},"Gastroenterology Associates of Central Georgia ( Site 1060)","Macon","Georgia","31201",{"type":61,"coordinates":126},[127,128],-83.6324,32.84069,{"lat":128,"lon":127},[131],{"name":68,"role":48,"phone":132,"phoneExt":40,"email":40},"478-464-2600",{"facility":134,"status":54,"city":135,"state":136,"zip":137,"country":58,"countryCode":59,"cosmosGeoPoint":138,"geoPoint":142,"contacts":143},"University of Kansas Medical Center ( Site 1077)","Kansas City","Kansas","66160",{"type":61,"coordinates":139},[140,141],-94.62746,39.11417,{"lat":141,"lon":140},[144],{"name":68,"role":48,"phone":145,"phoneExt":40,"email":40},"913-588-6019",{"facility":147,"status":54,"city":148,"state":149,"zip":150,"country":58,"countryCode":59,"cosmosGeoPoint":151,"geoPoint":155,"contacts":156},"Tulane University School of Medicine ( Site 1073)","New Orleans","Louisiana","70112",{"type":61,"coordinates":152},[153,154],-90.07507,29.95465,{"lat":154,"lon":153},[157],{"name":68,"role":48,"phone":158,"phoneExt":40,"email":40},"504-988-5110",{"facility":160,"status":54,"city":161,"state":162,"zip":163,"country":58,"countryCode":59,"cosmosGeoPoint":164,"geoPoint":168,"contacts":169},"BVL Research - Kansas ( Site 1054)","Liberty","Missouri","64068",{"type":61,"coordinates":165},[166,167],-94.41912,39.24611,{"lat":167,"lon":166},[170],{"name":68,"role":48,"phone":171,"phoneExt":40,"email":40},"816-222-4241",{"facility":173,"status":54,"city":174,"state":175,"zip":176,"country":177,"countryCode":40,"cosmosGeoPoint":178,"geoPoint":182,"contacts":183},"Wonju Severance Christian Hospital ( Site 1602)","Wŏnju","Kang-won-do","26426","South Korea",{"type":61,"coordinates":179},[180,181],127.94528,37.35139,{"lat":181,"lon":180},[184],{"name":68,"role":48,"phone":185,"phoneExt":40,"email":40},"+82 33 741 0505",{"facility":187,"status":54,"city":188,"state":40,"zip":189,"country":177,"countryCode":40,"cosmosGeoPoint":190,"geoPoint":194,"contacts":195},"Kangbuk Samsung Hospital ( Site 1601)","Seoul","03181",{"type":61,"coordinates":191},[192,193],126.9784,37.566,{"lat":193,"lon":192},[196],{"name":68,"role":48,"phone":197,"phoneExt":40,"email":40},"+82-2-2001-8556",{"type":199,"investigatorFullName":40,"investigatorTitle":40,"investigatorAffiliation":40,"oldNameTitle":40,"oldOrganization":40},"SPONSOR","100628557","phase-2-a-study-to-evaluate-efficacy-and-safety-of-mk-8690-in-participants-with-moderately-to-severely-active-ulcerative-colitis-mk-8690-002-100628557",false,"NCT07463183","A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)","A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-8690 in Adult Participants With Moderately to Severely Active Ulcerative Colitis","The main inclusion criteria include but are not limited to the following:\n\n* Has had ulcerative colitis (UC) (from onset of symptoms) for at least 3 months before Randomization\n* Has moderately to severely active UC\n* Has a weight ≥40 kg\n* Satisfies at least 1 of the criteria: Has had an inadequate response or loss of response to 1 or more protocol-specified treatments; protocol specified corticosteroid dependence; has been intolerant to 1 or more protocol-specified UC treatments\n* Is on treatment with any protocol-specified drugs during the study and meets drug stabilization requirements, as applicable\n\nThe main exclusion criteria include but are not limited to the following:\n\n* Has a diagnosis of Crohn's Disease (CD) or indeterminate colitis (inflammatory bowel disease (IBD)-undefined) or other types of colitis or enteritis that may confound efficacy assessment\n* Has a current diagnosis of fulminant colitis and\u002For toxic megacolon\n* Has UC limited to the rectum\n* Has a current or impending need for colostomy or ileostomy\n* Has had a total proctocolectomy or partial colectomy\n* Has UC exacerbation requiring hospitalization within 2 weeks before Screening\n* Has any active infection as specified in the protocol\n* Is known to be infected with hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV)\n* Has evidence of active tuberculosis (TB) or meets TB exclusionary parameters\n* Has a history of cancer (except fully treated nonmelanoma skin cell cancers or cervical carcinoma in situ after complete surgical removal) and is disease free for \\\u003C5 years before Randomization or has a history of colorectal cancer at any time\n* Has prior or current evidence of definite colonic dysplasia except for low-grade dysplasia that has been completely removed\n* Has had major surgery within 3 months before Screening or has a major surgery (ie, surgical procedure requiring general anesthesia) planned during the study\n* Has received protocol-specified prohibited medications","ALL","18 Years","75 Years",{"count":211,"type":212},100,"ESTIMATED","INTERVENTIONAL",[215],"PHASE2","The purpose of this protocol is to evaluate the efficacy of MK-8690 in participants with moderately to severely active ulcerative colitis. The primary hypothesis is that MK-8690 is superior to placebo with respect to the proportion of participants achieving clinical remission per Modified Mayo Score at Week 12.",[218,219],"Colitis Ulcerative","Ulcerative Colitis","2026-07-01",{"date":222,"type":223},"2026-07-02","ACTUAL",{"date":225,"type":223},"2026-03-24",{"date":227,"type":212},"2028-12-21",{"name":5,"class":6},11]